Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds High upfront costs make it hard for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies in the pipeline. A combination of installment plans and value-based contracting will likely be the wave of the future for gene therapy reimbursement.